Kilkof

Indications

• Acne vulgaris
• Acute promyelocytic leukemia (APL)
• Cytotoxic responsive malignancies

Dosage

Children: For children, consult local protocols or BNF for Children for specific dosing regimens.

Adults: For acute promyelocytic leukemia, the recommended dose is 45 mg/m2 daily in two divided doses for a maximum duration of 90 days.

Mechanism of action

Tretinoin exerts its pharmacological effects by binding to and activating retinoic acid receptors (RARs) and retinoid X receptors (RXRs) in the nucleus. This binding induces transcriptional regulation of genes involved in cell differentiation and proliferation. In skin conditions, it enhances keratinocyte turnover and reduces inflammation, while in APL, it promotes differentiation of leukemic cells.

Pharmacodynamics

Tretinoin promotes cell production, proliferation, and differentiation, primarily affecting epidermal cells. Topically, it regulates epidermal turnover and collagen synthesis, thereby preventing collagen degradation and enhancing skin appearance. It also exhibits antineoplastic effects by inducing cytodifferentiation in tumor cells, particularly in APL, leading to decreased proliferation of leukemic cells.

Pharmacokinetics

Tretinoin is well absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. It is extensively metabolized in the liver, primarily through oxidation and conjugation, yielding several active and inactive metabolites. The elimination half-life ranges from 0.5 to 2 hours, and its metabolites are excreted in urine. The pharmacokinetics may be affected by liver function, necessitating caution in hepatic impairment.

Contra-indications

• Pregnancy
• Breastfeeding
• Hypersensitivity to tretinoin
• History of depression or severe neuropsychiatric reactions

Adverse effects

• Headache
• Dizziness
• Nausea
• Vomiting
• Abdominal pain
• Dry skin
• Erythema
• Chills
• Insomnia
• Intracranial hypertension
• Visual impairment
• Emotional lability
• Increased risk of thromboembolism
• Hypercalcemia
• Tinnitus
• Skin reactions

Interactions

• Tretinoin and vitamin A: Severe (increases risk of vitamin A toxicity)
• Tretinoin and posaconazole: Moderate (increases risk of tretinoin toxicity)

Precautions

• Caution in hepatic impairment
• Monitor haematological and coagulation profile, liver function, serum calcium, and plasma lipids before and during treatment
• Risk of neuropsychiatric reactions; advise patients to seek medical attention for mood changes

Pregnancy

Tretinoin is teratogenic; avoid use during pregnancy.

Breast-feeding

Avoid; discontinue breastfeeding during treatment.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Capsules (75 mg)
• Solution for injection
• Topical formulations (cream or gel)

Indications

• Infections (topical treatment)
• Wound care (as an antiseptic)
• Ear infections (as an ear drop solution)
• Acid-base balance in metabolic acidosis

Dosage

Children: Refer to established guidelines as dosage may vary based on the formulation and indication.

Adults: Refer to established guidelines as dosage may vary based on the formulation and indication.

Mechanism of action

Acetic acid exerts its effects primarily through its ability to lower pH levels, creating an acidic environment which is inhospitable to many pathogens. It can disrupt the integrity of microbial cell membranes, leading to cell lysis and death. Additionally, acetic acid can promote the healing of wounds and enhance the absorption of certain medications when used as a solvent.

Pharmacodynamics

The pharmacodynamics of acetic acid involve its interaction with biological systems, leading to changes in cellular functions. Its acidic nature helps in the denaturation of proteins and disruption of microbial metabolism. This contributes to its antibacterial and antifungal activities, making it effective against a range of pathogens.

Pharmacokinetics

Acetic acid is rapidly absorbed in the gastrointestinal tract when ingested. It is metabolized primarily in the liver, converting to acetyl CoA and subsequently entering various metabolic pathways including the citric acid cycle. The elimination half-life varies but is generally short, with excretion occurring mainly via urine. When applied topically, absorption is minimal, and local effects are predominant.

Pregnancy

The safety of acetic acid during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

There is no specific information available regarding the use of acetic acid during breastfeeding. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep tightly closed in a well-ventilated area.

Indications

• Surgical procedures requiring anesthesia
• Pain management in various medical procedures
• Diagnostic procedures that require patient immobility
• Regional anesthesia for pain relief during childbirth

Dosage

Children: Pediatric dosing is highly variable and should be tailored to the child's age, weight, and the specific anesthetic agent used. Refer to specialized pediatric anesthesia guidelines for dosing information.

Adults: Dosing varies widely based on the specific anesthetic used, the procedure, and the individual patient's characteristics. Refer to specific anesthetic guidelines for detailed dosing information.

Mechanism of action

Anesthetics act primarily by modulating neurotransmission in the central nervous system. General anesthetics enhance inhibitory neurotransmission, primarily through gamma-aminobutyric acid (GABA) receptors, while inhibiting excitatory neurotransmission at glutamate receptors. Local anesthetics block sodium channels in neuronal membranes, preventing the generation and conduction of nerve impulses, leading to loss of sensation in the targeted area.

Pharmacodynamics

The pharmacodynamics of anesthetics involve their effects on the nervous system, including alterations in consciousness, pain perception, and muscle relaxation. General anesthetics induce a reversible state of unconsciousness and immobility, while local anesthetics provide localized numbing. The onset and duration of action depend on the specific agent used, its formulation, and the site of administration.

Pharmacokinetics

Anesthetics are absorbed and distributed rapidly due to their lipophilic nature. General anesthetics are typically administered via inhalation or intravenous routes, with rapid onset and offset of action. Metabolism occurs primarily in the liver, while excretion is primarily via the lungs for inhaled agents and the kidneys for those metabolized by the liver. Local anesthetics are absorbed systemically, but their effects are localized to the site of administration, with metabolism occurring in the liver and excretion through the kidneys.

Contra-indications

• Hypersensitivity to the drug or its components
• Severe respiratory depression
• Acute porphyria
• Known malignant hyperthermia

Adverse effects

• Nausea and vomiting
• Dizziness
• Hypotension
• Respiratory depression
• Allergic reactions
• Cardiovascular instability

Interactions

• Opioids may enhance the sedative effects
• Benzodiazepines can increase the risk of respiratory depression when used together
• Certain muscle relaxants may have additive effects

Precautions

• Use with caution in patients with a history of substance abuse
• Monitor patients with cardiovascular disease closely
• Caution in patients with compromised respiratory function
• Consider potential drug interactions with other CNS depressants

Pregnancy

Use during pregnancy should be avoided unless absolutely necessary, as risks versus benefits must be considered.

Breast-feeding

Consult a healthcare professional before use, as the drug may pass into breast milk.

Storage

Store in a cool, dry place, away from direct light. Keep out of reach of children.

Formulations

• Injectable solution
• Inhalation gas
• Topical formulation

Indications

• Dyspepsia
• Flatulence
• Bloating
• Cough relief
• Antimicrobial support

Dosage

Children: Consult appropriate pediatric herbal guidelines, as specific dosing is not universally established.

Adults: Refer to herbal supplement guidelines for dosing, as specific doses can vary widely based on preparation and concentration.

Mechanism of action

Aniseed contains several active compounds, including anethole, which is believed to exert its effects primarily through modulation of the gastrointestinal system. Anethole can stimulate the secretion of digestive enzymes and has been shown to possess antispasmodic properties, potentially alleviating symptoms related to gastrointestinal discomfort. Additionally, its antimicrobial properties may contribute to inhibiting the growth of certain pathogens.

Pharmacodynamics

The pharmacodynamic profile of aniseed is characterized by its ability to enhance digestive function and alleviate symptoms of dyspepsia. Its antispasmodic effects are mediated through inhibition of smooth muscle contractions in the gut. Aniseed may also exhibit mild sedative properties, contributing to its use as a calming herbal remedy. The overall effect is a combination of digestive support and potential relief from gastrointestinal discomfort.

Pharmacokinetics

The pharmacokinetics of aniseed components, particularly anethole, involve oral absorption followed by distribution throughout the body. Anethole is metabolized in the liver and excreted primarily in the urine. The onset of action can vary based on the form of administration, with herbal teas generally producing effects within a few hours, while concentrated extracts may have a more rapid onset. The duration of action is also influenced by the dose and form used.

Adverse effects

• Allergic reactions
• Dermatitis
• Gastrointestinal upset

Interactions

• May interact with anticoagulants, increasing the risk of bleeding
• Can enhance the effects of sedative medications

Precautions

• Use with caution in individuals with a history of allergies, particularly to plants in the Apiaceae family
• May cause skin irritation in sensitive individuals

Pregnancy

Generally considered safe when used in culinary amounts, but high doses should be avoided due to potential hormonal effects.

Breast-feeding

Considered safe when used in culinary amounts, but high doses should be avoided.

Storage

Store in a cool, dry place away from direct sunlight and moisture.

Formulations

• Whole seeds
• Essential oil
• Ground powder

Indications

• Topical antiseptic
• Skin irritations
• Minor cuts and abrasions
• Protective barrier for skin

Dosage

Children: The dosage for paediatric patients should be determined based on the specific product and clinical condition. Refer to the BNF for Children for guidance.

Adults: The dosage for adults varies based on formulation and condition treated. Refer to specific product guidelines.

Mechanism of action

Benzoin acts as a mild antiseptic and astringent. It is thought to exert its effects by forming a protective barrier on the skin and mucous membranes, helping to prevent infection and promote healing. The exact mechanism of action at the molecular level is not fully elucidated; however, it may involve the stabilization of cell membranes and modulation of inflammatory responses.

Pharmacodynamics

Benzoin exhibits local irritant effects when applied topically. It stimulates the sensory nerves in the skin, leading to increased blood flow and promoting the healing process. Its astringent properties help to reduce secretions and tighten tissues, which can be beneficial in conditions involving skin irritation or inflammation.

Pharmacokinetics

The pharmacokinetics of benzoin, when applied topically, are characterized by minimal systemic absorption. It primarily acts at the site of application. Any absorption that occurs is limited, and hence, systemic effects are rare. The duration of action is influenced by the formulation and the condition of the skin at the application site.

Pregnancy

Safety in pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Use with caution. It is not known whether benzoin is excreted in human milk.

Storage

Store in a well-closed container at room temperature. Protect from light.

Formulations

• {'formulation': 'Benzoin tincture', 'concentration': 'Various concentrations available'}
• {'formulation': 'Benzoin resin', 'concentration': 'Available as powdered resin'}

Indications

• Topical pain relief for conditions such as osteoarthritis and neuropathic pain
• Management of postherpetic neuralgia
• Supportive treatment for muscle and joint pain
• Stimulation of digestion and appetite

Dosage

Children: Dosage for pediatric patients should be determined by a healthcare provider, taking into consideration

Adults: Topical formulations generally recommend application to the affected area, with specific dosing instructions provided by the product label. For oral supplements, follow the manufacturer's guidelines or consult a healthcare professional.

Mechanism of action

Capsaicin, the main active component in Capsicum, exerts its effects by binding to the TRPV1 (transient receptor potential vanilloid 1) receptor, which is a cation channel involved in the transmission of pain and heat sensations. This binding leads to the depolarization of sensory neurons, resulting in the release of substance P, a neuropeptide associated with pain signaling. Continuous exposure to capsaicin results in the desensitization of these receptors, leading to decreased pain perception over time.

Pharmacodynamics

The analgesic properties of Capsicum are attributed to its ability to alter the perception of pain. Capsaicin induces a sensation of warmth and pain initially, which is followed by a prolonged analgesic effect due to the depletion of substance P from the nerve endings. Additionally, Capsicum may exhibit anti-inflammatory effects through the modulation of cytokine release and inhibition of inflammatory pathways, contributing to its therapeutic applications in pain management and inflammatory conditions.

Pharmacokinetics

Capsaicin is poorly absorbed when ingested orally, but it can be effectively absorbed through the skin when applied topically. After application, it is metabolized by the liver, and its metabolites are excreted primarily through the kidneys. The onset of action for topical preparations can vary, with effects often observed within hours. The duration of action may last from several hours to days, depending on the formulation and the area of application.

Adverse effects

• Burning sensation at the site of application
• Skin irritation or rash
• Gastrointestinal upset (if ingested)
• Allergic reactions

Precautions

• Avoid contact with eyes and mucous membranes
• Use caution in patients with sensitive skin
• Consult a healthcare professional before use in patients with underlying health conditions

Pregnancy

Capsicum is generally considered unsafe during pregnancy due to potential effects on the fetus. Pregnant women should consult a healthcare provider before use.

Breast-feeding

Capsicum should be used with caution during breastfeeding as it may affect milk production or flavor.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Topical ointments or creams
• Capsules
• Powdered form for oral use

Indications

• Food coloring
• Flavoring agent
• Culinary applications

Dosage

Children: Refer to food product specifications, as dosage varies based on application. No specific therapeutic dose exists.

Adults: Refer to food product specifications, as dosage varies based on application. No specific therapeutic dose exists.

Mechanism of action

Caramel's mechanism of action primarily involves its role as a colorant and flavor enhancer in food products. The heating process leads to the breakdown of sugar molecules, resulting in the formation of various compounds that contribute to its color and taste. These compounds may also interact with taste receptors, enhancing the sensory experience of food.

Pharmacodynamics

Caramel does not have pharmacological effects in the traditional sense, as it is primarily a food additive. Its primary role is to provide color and flavor to foods rather than exerting therapeutic effects. However, it can influence the palatability of food items, potentially affecting food intake and enjoyment.

Pharmacokinetics

As a food additive, caramel is generally not absorbed in significant quantities in the gastrointestinal tract. It is metabolized by gut bacteria and may be broken down into simple sugars and other metabolites. The exact metabolic pathway is not well defined, as caramel is considered a complex mixture rather than a single compound.

Pregnancy

Caramel is generally regarded as safe for consumption during pregnancy when used in food products.

Breast-feeding

Caramel is considered safe during breastfeeding when consumed in moderate amounts as part of food.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Liquid caramel
• Caramel powder
• Caramel syrup

Indications

• Oral hygiene
• Prevention of dental plaque
• Management of minor infections in the oral cavity

Dosage

Children: Refer to BNF for Children for appropriate formulations and guidance on paediatric use.

Adults: Refer to BNF for specific formulations and usage instructions. Typical concentrations in mouthwashes are around 0.05% to 0.1%.

Mechanism of action

Cetylpyridinium chloride functions as a cationic surfactant that interacts with microbial cell surfaces due to its positively charged hydrophilic region. This interaction disrupts bacterial membrane integrity, leading to leakage of cytoplasmic components, interference with cellular metabolism, and ultimately, cell death. Additionally, it inhibits the synthesis of insoluble glucan by streptococcal glucosyltransferase, adsorbs to enamel surfaces, and prevents bacterial co-adhesion, enhancing its effectiveness in oral hygiene.

Pharmacodynamics

Cetylpyridinium chloride exhibits rapid bactericidal effects against gram-positive pathogens and fungicidal activity against yeasts. It is classified as a cationic disinfectant with local effects, making it suitable for managing minor infections. Its surfactant properties contribute to its efficacy in reducing microbial load in oral care applications.

Pharmacokinetics

Cetylpyridinium chloride is characterized by poor systemic absorption when used topically; therefore, its effects are primarily local rather than systemic. This property allows it to exert its antimicrobial action in the mouth without significant absorption into the bloodstream, making it safe for use in oral care products.

Adverse effects

• Mouth irritation
• Taste alteration
• Dryness of the mouth
• Nausea
• Diarrhea

Precautions

• Use with caution in individuals with a history of hypersensitivity to cetylpyridinium chloride or other quaternary ammonium compounds.
• Avoid swallowing the product.
• Not recommended for use in children under a certain age without medical advice.

Pregnancy

Cetylpyridinium chloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is advised.

Breast-feeding

It is not known whether cetylpyridinium chloride is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.

Formulations

• Mouthwash
• Toothpaste
• Lozenges
• Mouth sprays

Dosage

Children: Chloroform is not indicated for pediatric use due to safety concerns and potential for toxicity. Refer to specific clinical guidelines for any related interventions or alternative agents.

Adults: Chloroform is not commonly used in clinical practice today and specific dosing recommendations should be referred to in relevant clinical guidelines or literature. It is important to note that due to its toxicity, chloroform usage is highly restricted.

Mechanism of action

Chloroform undergoes bioactivation primarily through covalent binding to lipids and proteins, particularly under anaerobic conditions with the presence of NADPH. This process is linked to the inhibition of cytochrome P450 and related mono-oxygenases, with biotransformation being mediated by phenobarbital-inducible P450 isozymes. The resultant oxidation products impair the monooxygenase system, potentially leading to protein aggregation.

Pharmacodynamics

Chloroform has a depressant effect on the central nervous system, leading to sedation and anesthesia at sufficient exposure levels. Its effect on cytochrome P450 enzymes suggests a mechanism that can alter drug metabolism and pharmacokinetics of concurrently administered medications, potentially leading to toxic accumulation or therapeutic failure.

Pharmacokinetics

Chloroform is rapidly absorbed through inhalation and dermal exposure, with distribution throughout the body, including the liver and brain. It is metabolized primarily in the liver via the cytochrome P450 system, leading to the formation of reactive intermediates. Chloroform and its metabolites are eliminated through exhalation and renal excretion, but the potential for accumulation and toxicity remains a concern.

Pregnancy

Chloroform is not recommended for use during pregnancy due to potential risks to fetal development.

Breast-feeding

Chloroform is not recommended during breastfeeding as it may be excreted in breast milk and could pose risks to the infant.

Storage

Store in a cool, dry place away from light, in a tightly sealed container.

Indications

• General anesthesia
• Induction of anesthesia
• Sedation in surgical procedures

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and weight.

Adults: Dosage varies depending on the procedure and patient characteristics; refer to specific clinical guidelines.

Mechanism of action

The exact mechanism of action of diethyl ether is not completely understood. It is believed to produce reversible loss of consciousness through interactions with membrane lipids and hydrophobic regions of membrane-bound proteins. The drug may alter the function of ion channel proteins, potentially affecting the GABA receptor, which is implicated in the modulation of neuronal excitability. Additionally, ether has been shown to increase plasma levels of adrenaline and noradrenaline, suggesting stimulation of neurosympathetic and adrenomedullary functions.

Pharmacodynamics

Ether induces general anesthesia characterized by a reversible loss of sensation and consciousness. Its anesthetic properties are thought to be the result of its effects on neuronal signaling and neurotransmitter systems, primarily by enhancing inhibitory neurotransmission through GABAergic pathways, leading to decreased neuronal excitability and a sedative effect.

Pharmacokinetics

Diethyl ether is rapidly absorbed through the lungs and is distributed widely in body tissues due to its lipophilicity. It is metabolized primarily in the liver, and elimination occurs through exhalation and minor metabolic pathways. The onset of action is swift, with effects seen within minutes of inhalation, and recovery is equally rapid upon cessation of exposure.

Adverse effects

• Nausea
• Vomiting
• Respiratory depression
• Cardiovascular instability
• Hypotension
• Delayed recovery from anesthesia

Interactions

• May potentiate the effects of other central nervous system depressants
• Increased risk of respiratory depression when used with opioids
• Potential interaction with alcohol, leading to enhanced sedation

Precautions

• Use with caution in patients with respiratory or cardiovascular diseases
• Monitor for signs of respiratory depression
• Ensure appropriate equipment and personnel are available for anesthesia

Pregnancy

Use is contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Use with caution; limited data available on excretion in breast milk.

Storage

Store in a cool, dry place, away from heat and direct sunlight. Keep tightly closed.

Formulations

• Inhalation solution
• Liquid for inhalation

Indications

• Cough relief
• Sore throat
• Wound healing
• Skin irritation
• Digestive issues

Dosage

Children: For children over 1 year of age, a common dosage is 1 to 2 teaspoons of honey for cough relief. Honey should not be given to children under 1 year due to the risk of botulism.

Adults: For cough relief, a common recommendation is to take 1 to 2 tablespoons of honey, as needed. Honey can be taken directly or mixed with warm water or herbal teas.

Mechanism of action

Honey exhibits various mechanisms of action, including its antibacterial and anti-inflammatory properties. The high sugar concentration creates a hypertonic environment that inhibits the growth of bacteria. Additionally, honey contains hydrogen peroxide, methylglyoxal, and flavonoids that contribute to its antimicrobial effects. The antioxidant properties of honey help in mitigating oxidative stress and promoting wound healing.

Pharmacodynamics

The pharmacodynamics of honey involve its ability to promote healing and provide symptomatic relief from coughs and sore throats. Honey's viscosity and stickiness can coat the throat, providing a soothing effect and reducing irritation. Its natural sugars also serve as an energy source, while its antioxidants may help in reducing inflammation and promoting overall health.

Pharmacokinetics

Honey is primarily absorbed in the gastrointestinal tract. The sugars in honey are rapidly metabolized, providing quick energy. The absorption rate can vary based on the composition of the honey and individual digestive factors. Honey's components, including vitamins and minerals, may also have varying rates of absorption depending on the specific nutrient and the individual's metabolism.

Adverse effects

• Allergic reactions in sensitive individuals
• Botulism in infants under 1 year

Precautions

• Should not be given to infants under 1 year due to the risk of botulism
• Use with caution in individuals with known allergies to bee products

Pregnancy

Generally considered safe for use in pregnancy, but should be consumed in moderation.

Breast-feeding

Considered safe for breastfeeding mothers and their infants over 1 year of age.

Storage

Store in a cool, dry place away from direct sunlight. Keep tightly sealed.

Formulations

• Raw honey
• Pasteurized honey
• Honey in various food products

Indications

• Use as a preservative in pharmaceutical formulations
• Antimicrobial agent in cosmetic and food products
• Potential use in the management of inflammatory conditions due to salicylate biosynthesis

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to the specific product guidelines and BNF for appropriate dosing information.

Mechanism of action

Hydroxybenzoate functions primarily as a preservative by inhibiting the growth of microorganisms. It exerts its effects through the disruption of microbial cell metabolism, thereby preventing spoilage and degradation. The compound is involved in various biosynthetic pathways, including the production of salicylates, which possess anti-inflammatory properties.

Pharmacodynamics

Hydroxybenzoate displays antimicrobial activity against a range of bacteria and fungi. Its efficacy is influenced by factors such as pH and concentration, with higher concentrations generally leading to greater antimicrobial effects. The compound may also exhibit antioxidant properties, contributing to its protective effects in various formulations.

Pharmacokinetics

The pharmacokinetics of hydroxybenzoate involves its absorption, distribution, metabolism, and excretion. It is readily absorbed when applied topically or ingested. Once in the system, it is metabolized primarily in the liver, with metabolites excreted through the urine. The elimination half-life may vary based on the formulation and route of administration.

Pregnancy

There is limited information available regarding the safety of hydroxybenzoate during pregnancy. Consult a healthcare provider for advice.

Breast-feeding

It is unclear if hydroxybenzoate is excreted in human milk. Consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Acute poisoning
• Overdose of certain toxins
• As an emetic in specific clinical scenarios

Dosage

Children: For children, the dosage is typically 10 to 15 mL of syrup of ipecac for children aged 1 year and older. Again, it is crucial to seek guidance from a poison control center or healthcare provider.

Adults: For adults, the typical dose for inducing emesis is 15 to 30 mL of syrup of ipecac, taken orally. However, due to the risks associated with its use, consultation with a poison control center or healthcare provider is recommended for specific situations.

Mechanism of action

Ipecacuanha contains alkaloids such as emetine and cephaeline, which stimulate the chemoreceptor trigger zone in the medulla oblongata, leading to the induction of vomiting. These compounds also increase gastric motility and secretions, further contributing to its emetic effect.

Pharmacodynamics

The emetic action of ipecacuanha is dose-dependent, with lower doses potentially causing nausea without vomiting, while higher doses can lead to significant emesis. Its effects are mediated through the central nervous system and gastrointestinal tract.

Pharmacokinetics

Ipecacuanha is absorbed through the gastrointestinal tract, with peak plasma concentrations occurring within 1-3 hours after administration. The elimination half-life and specific metabolic pathways of the active components are not well characterized, but they are believed to be metabolized in the liver and excreted primarily in urine.

Contra-indications

• Hypersensitivity to ipecacuanha
• Use in patients with a known or suspected bowel obstruction
• Concurrent use of emetics or in cases of poisoning with corrosive substances

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Drowsiness
• Cardiac arrhythmias
• Hypotension

Interactions

• May interact with other emetics or central nervous system depressants
• Potential for altered absorption of orally administered medications due to vomiting

Precautions

• Use with caution in patients with a history of cardiac issues
• Monitor for dehydration due to vomiting
• Not recommended for use in children without professional supervision

Pregnancy

Ipecacuanha is not recommended during pregnancy due to potential for adverse effects.

Breast-feeding

Caution is advised when using ipecacuanha while breastfeeding, as it may affect the infant.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Syrup
• Powder
• Capsules

Indications

• Allergic conditions
• Autoimmune diseases
• Asthma and chronic obstructive pulmonary disease (COPD)
• Certain cancers (e.g., leukemia, lymphoma)
• Skin conditions (e.g., dermatitis)
• Inflammatory bowel disease
• Multiple sclerosis exacerbations
• Severe infections requiring immunosuppression

Dosage

Children: Refer to BNF for Children for specific dosing; doses vary significantly based on the child's age, weight, and condition being treated.

Adults: Refer to BNF for specific dosing; typically, initial doses range from 4 to 48 mg depending on the severity of the condition.

Mechanism of action

Methylprednisolone exerts its effects by binding to glucocorticoid receptors, leading to the modulation of gene expression. This interaction influences the transcription of anti-inflammatory proteins while suppressing the expression of pro-inflammatory genes, ultimately resulting in reduced inflammation and immune response.

Pharmacodynamics

The pharmacodynamic effects of methylprednisolone are characterized by its ability to decrease inflammation, suppress the immune response, and affect carbohydrate metabolism. Therapeutic doses lead to various systemic effects, including modification of leukocyte distribution and inhibition of cytokine production.

Pharmacokinetics

Methylprednisolone is well absorbed after oral administration, with a bioavailability of approximately 50%. It has a volume of distribution that reflects extensive tissue binding. The drug is metabolized primarily in the liver through conjugation and reduction, and its metabolites are excreted in urine. The half-life varies based on the route of administration but is generally around 18 to 36 hours.

Adverse effects

• Increased blood pressure
• Hyperglycemia
• Weight gain
• Mood changes
• Insomnia
• Gastrointestinal disturbances
• Increased susceptibility to infections

Interactions

• methylphenidate+apraclonidine: Severe (decreases effects)
• methylthioninium chloride+bupropion: Severe (increases risk of severe hypertension)
• methylphenidate+linezolid: Severe (increases risk of elevated blood pressure)
• rasagiline+methylphenidate: Severe (increases risk of a hypertensive crisis)
• mao-inhibitors+methylphenidate: Severe (increases risk of a hypertensive crisis)
• dronedarone+methylprednisolone: Moderate (increases exposure)
• miconazole+methylprednisolone: Moderate (increases concentration)
• antifungals, azoles+methylprednisolone: Moderate (increases exposure)
• crizotinib+methylprednisolone: Moderate (increases exposure)

Precautions

• Use with caution in patients with hypertension
• Monitor blood glucose levels in diabetic patients
• Consider potential for infection risk due to immunosuppression
• Evaluate for psychiatric effects in susceptible individuals

Pregnancy

Corticosteroids may be used during pregnancy if the potential benefit justifies the risk to the fetus. Careful monitoring is advised.

Breast-feeding

Corticosteroids are excreted in breast milk; caution is advised. Monitor the infant for potential effects.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Tablets
• Injectable solutions
• Topical preparations

Mechanism of action

Methylsulphate functions as a methylating agent, transferring a methyl group to nucleophiles. This process involves the formation of a sulfonium ion, which is highly reactive and can readily react with nucleophilic sites on various substrates, leading to methylation reactions.

Pharmacodynamics

The pharmacodynamics of methylsulphate is primarily related to its role as a methylating agent in biochemical reactions. It can alter the structure and function of biological molecules, potentially affecting cellular processes and signaling pathways. However, detailed pharmacodynamic studies specific to therapeutic use are limited.

Pharmacokinetics

There is limited information on the pharmacokinetics of methylsulphate, given its typical use as a reagent in laboratory settings rather than a clinical drug. When used in chemical reactions, its reactivity and transformation into other compounds would dictate its pharmacokinetic profile, which could vary significantly based on the specific context of use.

Pregnancy

There is limited data on the use of methylsulphate in pregnancy. Consult relevant guidelines.

Breast-feeding

Data on the excretion of methylsulphate in human milk is not available. Caution is advised.

Storage

Store in a cool, dry place, away from direct sunlight.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Indications

• Source of energy
• Management of hypoglycemia
• Sports nutrition
• Dietary sweetening agent

Dosage

Children: Refer to specific dietary guidelines or consult a healthcare professional for individualized recommendations.

Adults: Refer to specific dietary guidelines or consult a healthcare professional for individualized recommendations.

Mechanism of action

Sugars are metabolized by various pathways in the body, primarily through glycolysis. Glucose, for instance, is transported into cells via glucose transporters and phosphorylated to glucose-6-phosphate, which can then enter the glycolytic pathway to produce ATP, the energy currency of the cell. Additionally, sugars can affect insulin secretion, with glucose stimulating pancreatic beta cells to release insulin. This hormone facilitates the uptake of glucose by tissues, particularly muscle and adipose tissue.

Pharmacodynamics

The pharmacodynamics of sugars involve their role in energy metabolism and homeostasis. Upon ingestion, sugars are rapidly absorbed in the gastrointestinal tract and lead to an increase in blood glucose levels. This triggers insulin release, promoting glucose uptake and utilization by tissues. Excess glucose can be stored as glycogen in the liver and muscle or converted to fat for long-term energy storage. The regulation of blood sugar levels is critical, as both hyperglycemia and hypoglycemia can lead to significant health complications.

Pharmacokinetics

Sugars are quickly absorbed in the intestines, with their peak plasma concentrations occurring within 30 minutes to 2 hours after ingestion, depending on the type of sugar consumed. The metabolism of sugars occurs primarily in the liver, where they can be converted to glucose or stored as glycogen. The elimination half-life of simple sugars is not defined in the same way as drugs, as they are continuously metabolized and utilized by the body, with excess being stored or excreted as needed.

Adverse effects

• Hyperglycemia
• Weight gain
• Dental caries
• Gastrointestinal upset

Interactions

• May affect the absorption of certain medications when consumed in excess
• Potential interaction with insulin and other antidiabetic medications

Precautions

• Use with caution in patients with diabetes mellitus or insulin resistance
• Monitor blood glucose levels in patients with a history of hyperglycemia
• Consider dietary guidelines for individuals with metabolic syndrome

Pregnancy

Sugars are generally safe during pregnancy, but excessive intake should be avoided to prevent gestational diabetes.

Breast-feeding

Sugars are safe during breastfeeding; however, a balanced diet is recommended to support maternal and infant health.

Storage

Store in a cool, dry place away from moisture and direct sunlight. Keep container tightly closed.

Formulations

• Granulated sugar
• Brown sugar
• Powdered sugar
• Liquid sugar
• High fructose corn syrup

Indications

• Herbal remedy for anxiety
• Support for digestive health
• Anti-inflammatory support
• Antimicrobial effects
• Pain relief
• Support for immune function

Dosage

Children: Refer to specific tincture product instructions for dosage, as this varies significantly based on the plant and concentration.

Adults: Refer to specific tincture product instructions for dosage, as this varies significantly based on the plant and concentration.

Mechanism of action

The mechanism of action of tinctures depends on the specific herbs or plants used in their preparation. Generally, the active compounds extracted from the plant material interact with various biological pathways, including receptor modulation, enzyme inhibition, and antioxidant activity. For example, flavonoids and alkaloids found in many tinctures may exhibit anti-inflammatory, analgesic, or antimicrobial effects through their interaction with cellular signaling pathways.

Pharmacodynamics

The pharmacodynamics of tinctures is influenced by the specific constituents of the herbal material. These constituents may exert effects such as enhancing or inhibiting neurotransmitter activity, modulating inflammatory responses, or influencing metabolic pathways. The effects can vary widely among different tinctures based on the plant used, the extraction method, and the concentration of the active ingredients.

Pharmacokinetics

The pharmacokinetics of tinctures involves absorption, distribution, metabolism, and excretion of the active compounds. After administration, the alcohol or vinegar solvent aids in the rapid absorption of these compounds through the mucosal membranes or gastrointestinal tract. Once absorbed, the compounds are distributed throughout the body and may undergo metabolic transformations primarily in the liver. The elimination half-life varies based on the specific herb and its active constituents, with some compounds being excreted unchanged while others are metabolized into active or inactive metabolites.

Contra-indications

• Hypersensitivity to any component of the tincture
• Severe liver disease
• Pregnancy (specific tinctures may vary)

Adverse effects

• Skin irritation
• Allergic reactions
• Gastrointestinal upset
• Drowsiness or sedation (depending on the active ingredient)

Interactions

• May interact with alcohol, increasing sedative effects
• Potential interactions with other CNS depressants
• May affect the metabolism of certain drugs via hepatic pathways

Precautions

• Use cautiously in patients with a history of substance abuse
• Monitor liver function in patients with liver disease
• Caution in operating machinery or driving due to potential drowsiness

Pregnancy

Generally not recommended during pregnancy due to potential risks associated with alcohol and other active ingredients.

Breast-feeding

Caution is advised, as components may pass into breast milk and affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep tightly closed and out of reach of children.

Formulations

• Tinctures of various herbs and compounds, including but not limited to: echinacea, valerian, and calendula

Dosage

Children: There are no established therapeutic doses for toluene in the pediatric population. Exposure should be avoided due to potential toxicity.

Adults: There are no established therapeutic doses for toluene as it is primarily used as an industrial solvent. Exposure should be minimized due to its toxic effects.

Mechanism of action

Toluene exerts its effects primarily through its interaction with the central nervous system. It acts as a neurotoxin and can influence neurotransmitter systems, particularly those involving gamma-aminobutyric acid (GABA) and glutamate. The exact pathways are not fully elucidated, but toluene is known to enhance GABAergic activity, leading to sedative and anxiolytic effects, while also disrupting glutamate signaling, which can contribute to neurotoxicity.

Pharmacodynamics

The pharmacodynamics of toluene involve its effects on the central nervous system, where it can lead to a range of symptoms from euphoria and intoxication to neurological impairment and respiratory depression at higher exposures. Chronic exposure may result in neurobehavioral deficits, cognitive dysfunction, and potential long-term neurological damage. The effects can vary significantly based on concentration, duration of exposure, and individual susceptibility.

Pharmacokinetics

Toluene is rapidly absorbed through inhalation and dermal routes, with peak blood concentrations occurring shortly after exposure. It is metabolized primarily in the liver via cytochrome P450 enzymes, leading to the formation of various metabolites, including benzyl alcohol and hippuric acid. These metabolites are excreted in the urine. The elimination half-life of toluene varies depending on the route of exposure and individual metabolic factors, generally ranging from a few hours to a day.

Pregnancy

Toluene is not recommended during pregnancy due to potential risks to fetal development. It may cause teratogenic effects.

Breast-feeding

Toluene may be excreted in breast milk, and its use is generally not recommended while breastfeeding due to potential harm to the nursing infant.

Storage

Store in a cool, dry place away from direct sunlight, heat, and ignition sources. Ensure containers are tightly sealed.

Indications

• Used as a thickening agent in food products
• Utilized in pharmaceutical formulations as a stabilizer
• Employed in cosmetics for texture improvement
• Applied in industrial products for its viscosity properties

Dosage

Children: Refer to specific product guidelines for appropriate use. Xanthan is used in formulations as a thickener or stabilizer, and dosage should be evaluated based on the specific product and formulation.

Adults: Refer to specific product guidelines for appropriate use. Xanthan is typically used in small quantities as a thickener or stabilizer in food and pharmaceutical products.

Mechanism of action

Xanthan functions primarily as a thickener and stabilizer. It acts by interacting with water molecules to form a gel-like consistency, which enhances the texture and stability of products. Its unique rheological properties allow it to maintain viscosity under varying conditions, which is beneficial in food and pharmaceutical applications.

Pharmacodynamics

Xanthan's action is primarily physical rather than pharmacological. It does not exert a direct therapeutic effect but influences the delivery and stability of active ingredients in formulations. The gel formation and viscosity changes help ensure the uniform distribution of substances in liquid formulations, which can improve the effectiveness of the drug delivery.

Pharmacokinetics

As xanthan is a polysaccharide, it is not absorbed in the gastrointestinal tract when ingested. It passes through the digestive system largely unchanged. In terms of metabolism, xanthan is broken down by colonic bacteria, resulting in short-chain fatty acids. Its pharmacokinetic profile indicates that it has a low bioavailability due to its large molecular size and structure.

Pregnancy

There is insufficient data on the use of xanthan during pregnancy. Consult a healthcare professional before use.

Breast-feeding

There is insufficient data on the excretion of xanthan in human milk. Consult a healthcare professional before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Xanthan gum powder

Mechanism of action

The exact mechanism of action of tretinoin in skin conditions and acute promyelocytic leukemia (APL) has not been fully elucidated; however, several proposed mechanisms exist. Tretinoin is believed to exert its pharmacological actions by binding to and activating two types of nuclear receptors - retinoic acid receptors (RARs) alpha, beta, and gamma and retinoid X receptors (RXRs). In the human skin, RARs (especially RAR-alpha) form heterodimers with RXR to act as inducible transcription regulators of genes involved in cell differentiation by binding to retinoic acid response elements. Tretinoin binds to RXRs to promote epidermal proliferation. It also blocks the actions of inflammatory mediators, enhancing procollagen production and collagen type I and III formations. Some animal and human studies suggest that tretinoin induces the expression of transforming growth factor beta (TGF-β), which stimulates the transcription of several types of collagen messenger RNA. Collagen formation curtails further solar UV-induced skin damage and aging processes. Acne is associated with abnormal follicular formation from excessive keratinization of epithelial cells. Tretinoin promotes cornified cell detachment and enhances keratinocyte shedding. It also stimulates mitotic activity and loosely-adherent corneocyte turnover to expel comedo contents, reducing microcomedo precursor lesions of acne vulgaris. Tretinoin may reduce epidermal melanin and pigmentation by increasing keratinocyte turnover and reducing tyrosinase activity. RAR-alpha and -beta have also been implicated in APL. APL is characterized by a t(15;17) chromosomal translocation, which fuses the promyelocytic myeloid leukemia (PML) gene with the RAR-alpha gene. The resulting PML-RAR-alpha fusion protein plays a role in the pathogenesis of APL by aberrating promyelocyte differentiation. The PML-RAR-alpha fusion protein is found to be predominant in leukemic cells, exerting a dominant negative effect on RAR, RXR and PML function. Tretinoin induces terminal differentiation in hemopoietic precursor cell lines and APL cells. Tretinoin is believed to promote caspase-mediated cleavage and proteasome-dependent degradation to cause apoptosis and degradation of the PML-RAR-alpha fusion protein. It may also convert the fusion protein from a transcription repressor to an activator. Although the precise mechanism(s) of action of tretinoin has not been fully elucidated, it is known that the drug is not a cytolytic agent. Tretinoin induces cellular differentiation and decreases the proliferation of acute promyelocytic leukemia (APL) cells. The PML/RAR-a fusion protein resulting from the chromosomal translocation appears to block myeloid differentiation at the promyelocyte stage, possibly by complexing and inactivating wild-type PML or by inhibiting the normal retinoic acid signaling pathway. In patients with APL who achieve a complete remission with tretinoin therapy, the drug causes an initial maturation of the primitive promyelocytes derived from the cellular leukemic clone followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells. Observations supporting cellular differentiation effects as a mechanism of tretinoin include the absence of bone marrow hypoplasia during induction, the appearance of immunophenotypically unique "intermediate cells" expressing both mature and immature cell surface antigens, and the presence of both Auer rods and the translocation in morphologically mature granulocytes until a late stage of induction. The mechanism by which the population of malignant cells is eliminated is not fully understood but appears to involve apoptosis (programmed cell death). Following induction therapy, the PML/RAR-a fusion protein can be detected in the majority of patients, suggesting that tretinoin alone does not eradicate the leukemic clone.

Pharmacodynamics

Tretinoin is a vitamin A derivative that promotes cell production, proliferation, and differentiation. When used topically, tretinoin regulates epidermal cell turnover and collagen production. It also prevents collagen loss, reduces inflammation, and blocks the induction of matrix metalloproteinase (MMP), which are enzymes that disrupt collagen and elastic fibres. In short-term and long-term studies, topical application of tretinoin at doses ranging from 0.001% to 0.1% was associated with improvements in clinical signs of photoaging and fine wrinkles, increased epidermal thickness, compaction of the stratum corneum, and decreased melanin content. It also improved melanocyte differentiation and distribution, promotion of epidermal hyperplasia, and angiogenesis. Tretinoin exhibits antineoplastic activities when given orally. Tretinoin was shown to induce differentiation in tumour cells. It induced cytodifferentiation and decreased acute promyelocytic leukemia (APL) cell proliferation in culture and _in vivo_. In patients with APL, tretinoin promoted the initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission.

Mechanism of action

When incorporated into mouthwashes, toothpastes, lozenges, or mouth sprays, cetylpyridinium chloride is expected to elicit a mechanism of action that decreases new dental plaque growth, decreases or removes existing dental plaque, diminishes the growth of pathogenic bacteria, and inhibits the production of virulence factors. Cetylpyridinium chloride is a quaternary ammonium compound that demonstrates a broad spectrum anti-bacterial activity. It possesses a cationic surface active agent surfactant which can absorb readily to oral surfaces. The molecules of this agent have both hydrophilic and hydrophobic groups. In action, the positively charged hydrophilic region of cetylpyridinium chloride molecules enables the compound to interact with microbial cell surfaces and even integrate into the bacterial cytoplasmic membrane. Consequently, there is a resultant disruption of bacterial membrane integrity causing a leakage of bacterial cytoplasmic components, interference with cellular metabolism, inhibition of cell growth, and ultimately - cell death. Moreover, cetylpyridinium chloride can also inhibit the synthesis of insoluble glucan by streptococcal glucosyltransferase, adsorb to pellicle-covered enamel, and inhibit co-adhesion of bacteria, and bind streptococcus mutans biofilms. This ability of cetylpyridinium chloride to be able to adsorb to pellicle covered enamel imparts substantivity to the compound molecules - that is retention in the mouth and continued antimicrobial activity for a period of time after rinsing. Taking these mechanisms into consideration, cetylpyridinium chloride may be considered an active ingredient that is effective in the treatment and prevention of bacterial or fungal disorders of the oropharyngeal cavity.

Pharmacodynamics

Cetylpyridinium chloride is considered a cationic disinfectant with properties and uses similar to other such cationic surfactants. In particular, cetylpyridinium chloride has demonstrated a rapid bactericidal and fungicide effect on gram-positive pathogens and yeasts, respectively. Cetylpyridinium chloride is subsequently utilized in a variety of preparations for the local treatment of minor infections. Despite the variety of formulations in which cetylpyridinium chloride may appear as an active ingredient, it is generally accepted that it only elicits a local effect owing to the compound's relatively poor absorption by route of exposure.

Mechanism of action

The feasibility of an oxygen-independent mechanism of chloroform bioactivation was indicated by the covalent binding to lipid and protein occurring in anaerobic incubations of chloroform and microsomes in the presence of NADPH. Under these conditions, the loss of cytochrome p450 and the inhibition of related mono-oxygenases were also observed. The chloroform anoxic biotransformation was negligible in uninduced microsomes and seemed to be catalyzed mainly by phenobarbital-inducible p450 isozymes. Biotransformation could also be supported by NADH as the source of reducing equivalents. Anaerobic metabolism of chloroform led to decreased levels of the main phenobarbital-induced p450 isozymes even at low chloroform concentration, and did not affect benzo(a)pyrene hydroxylase activity. These effects were not decreased by thiolic compounds. The oxidation products of chloroform caused a general impairment of the monoxygenase system, probably related to the formation of protein aggregates with very high molecular weight. In the presence of physiological concentrations of GSH, the targets of aerobically-produced metabolite were lipids, and, to a smaller extent, p450. At low chloroform concentrations and/or in the presence of GSH, the most changes to microsomal structures seemed to be produced by the reductively-formed intermediates.

Mechanism of action

The mechanism of action by which .... ethyl ether produce/s/ reversible loss of consciousness is still unclear. Anesthesia can be produced by a wide variety of chemical agents, ranging from inert rare gases to steriodal molecules. This apparent lack of specificity, together with the observation that general anesthesia can be reversed by high pressure, poses a unique pharmacological problem. Most theories concern interaction of anesthetics with either membrane lipids or hydrophobic regions of specificic membrane-bound proteins. One hypothesis is that the anesthetic changes the function of an ion channel protein by modifying the conformation of the protein. Some investigators suggest that the GABA receptor may be the ion channel protein that is affected by inhalation of anesthetic agents... The most appropriate concept for the mechanism of general anesthesia /may be/ a the heterogenous site of anesthetic action, including both lipid and protein membrane components linked with neuronal function. In chronically catheterized rats, diethyl ether increased plasma adrenaline and noradrenaline concentrations indicating that this drug stimulates both neurosympathetic and adrenomedullary functions. These effects appear to be centrally mediated, since ganglionic blockade or spinal transection completely counteracted the diethyl ether induced increases in plasma calcium levels. Hippocampal EEG signals derived from chronically implanted electrodes in the freely moving rat were recorded before and after administration of centrally acting drugs, and analyzed by power and coherence spectra. Diethyl ether induced a low frequency (3-6 c/s) theta power and coherence peak in the immobile rat, which was sensitive to atropine or scopolamine. The residue spectrum, defined as the EEG spectrum with the theta harmonics removed, was sensitive to centrally acting drugs. Diethyl ether suppressed fast waves of 50-100 c/s, and some conditions, enhanced 15-50 c/s waves. The plasma beta-endorphin responses to ether and handling stress were examined in animals of various ages. At each age studied there was a significant, stress-induced elevation of plasma beta-endorphin-like immunoreactivity levels were higher in animals 3,7, and 14 days of age than in adults. Cortical action potential activity is suppressed by ether anesthesia and is not affected when sensory fibers in the sciatic nerve are stimulated. Consequently, ether blocks sensory pathways to the cortex; the blockade occurs even before cortical activity is entirely suspended. In contrast, pentobarbital suppresses activity in the cortex without blocking the sensory path to it during sciatic nerve stimulation.